Genentech

Genentech is a pioneering biotechnology company founded in 1976 and considered the founder of the modern biotechnology industry. Based in South San Francisco, California, Genentech has been delivering on the promise of biotechnology for more than 45 years, dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. The company became a member of the Roche Group in March 2009, with its South San Francisco campus serving as headquarters for Roche pharmaceutical operations in the United States. Genentech operates with significant autonomy within Roche, maintaining its entrepreneurial startup spirit while leveraging the resources of a global pharmaceutical leader. The company's research and development efforts focus on four key therapeutic areas: angiogenesis, apoptosis (programmed cell death), the HER pathway, and B-cell biology. Genentech has established itself as the leading provider of anti-tumor therapeutics in the United States, with an extensive oncology portfolio including groundbreaking medicines such as Herceptin for HER2-positive breast cancer, Avastin for various cancers, Rituxan for blood cancers and autoimmune conditions, and Tecentriq for immunotherapy. The company's transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Beyond oncology, Genentech develops treatments across multiple therapeutic areas including ophthalmology, immunology, and rare diseases. With over 13,500 employees and more than 2,400 researchers, Genentech continues to maintain the broadest and most diverse pipeline in oncology with more than 20 immunotherapy molecules in development. The company's commitment to innovation is demonstrated through its FDA approvals, including the 2024 approval of Itovebi for PIK3CA-mutated breast cancer, which received Priority Review and Breakthrough Therapy Designation.